




ANNUAL REPORT
FOREST LABORATORIES, INC.
2003

—≡ YEAR ENDED MARCH 31, 2003 ≡—



Forest Laboratories develops, manufactures and markets pharmaceutical products principally in the United States and Europe. Forest's primary therapeutic markets include central nervous system disorders, hypertension and pulmonary disorders. Forest is currently developing additional compounds in these areas as well as in pain management and gastrointestinal disorders. Forest's principal products include Lexapro™, a selective serotonin reuptake inhibitor (SSRI) for the treatment of depression; Celexa™, also for depression; Benicar™,* an angiotensin receptor blocker (ARB) for the treatment of hypertension; and Aerobid®, a metered dose inhaler for treating asthma.


In the United States, Forest's branded pharmaceutical products are marketed directly by the Company's Forest Pharmaceuticals, Forest Therapeutics, Forest Healthcare and Forest Specialty Sales salesforces. The Company's generic products are marketed directly by its Inwood Laboratories, Inc. subsidiary.

In the United Kingdom, Ireland and certain export markets, Forest products are marketed by the Company's subsidiaries, Forest Laboratories U.K. and Forest Tosara Ltd.


Forest Laboratories common stock is traded on the New York Stock Exchange, trading symbol—FRX.

**Benicar is a registered trademark of Sankyo Pharma.*

NET REVENUES
(In thousands)



NET INCOME
(In thousands)




FINANCIAL HIGHLIGHTS

FISCAL YEARS ENDED MARCH 31,
(In thousands, except per share data)

	2003	2002
Net revenues	\$2,245,806	\$1,601,824
Income before income taxes	820,569	470,178
Income taxes	198,581	132,224
Net income	621,988	337,954
Net income per common and common equivalent share—diluted	\$1.66	\$0.91
Weighted average number of common and common equivalent shares outstanding—diluted	373,702	370,484

RESEARCH & DEVELOPMENT
(In thousands)



STOCKHOLDERS' EQUITY
(In thousands)

